AI Engines For more Details: Perplexity Kagi Labs You
Antimicrobial Properties: Methyl benzethonium chloride exhibits strong antimicrobial activity against a wide range of bacteria, fungi, and viruses. It is commonly used in topical antiseptic solutions, wound disinfectants, and hand sanitizers to prevent infections.
Skin Irritation: In some individuals, especially those with sensitive skin, methyl benzethonium chloride may cause skin irritation or allergic reactions. Symptoms of skin irritation may include redness, itching, burning sensation, or rash. It is essential to discontinue use if any adverse reactions occur and seek medical advice.
Eye Irritation: Direct contact with methyl benzethonium chloride can cause irritation to the eyes. In case of accidental exposure, immediate rinsing with water is recommended. Prolonged or repeated exposure to high concentrations of methyl benzethonium chloride may lead to more severe eye irritation or damage.
Respiratory Effects: Inhalation of aerosols or vapors containing methyl benzethonium chloride may irritate the respiratory tract, leading to coughing, throat irritation, or difficulty breathing. Proper ventilation is essential when using products containing methyl benzethonium chloride to minimize inhalation exposure.
Toxicity: Methyl benzethonium chloride is generally considered safe when used as directed in approved products and at appropriate concentrations. However, ingestion of large quantities or misuse of products containing methyl benzethonium chloride can lead to toxicity. Symptoms of acute toxicity may include nausea, vomiting, abdominal pain, diarrhea, and central nervous system effects. In severe cases, ingestion of high doses may cause systemic toxicity and require medical attention.
Environmental Impact: Methyl benzethonium chloride may have adverse effects on the environment if released into water bodies or soil. It is important to handle and dispose of products containing methyl benzethonium chloride responsibly to minimize environmental contamination.
Regulatory Considerations: Methyl benzethonium chloride is regulated by health authorities, and its use in certain products may be subject to restrictions or guidelines to ensure consumer safety. Users should follow label instructions and adhere to regulatory requirements when using products containing methyl benzethonium chloride.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3.1 | 0.1 |
| Allergies | 7.1 | 3.7 | 0.92 |
| Allergy to milk products | 2.2 | 1.6 | 0.38 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.7 | 8.2 | -0.22 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.8 | 1.2 | 2.17 |
| Ankylosing spondylitis | 4.9 | 1.8 | 1.72 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2 | 0.3 | 5.67 |
| Asthma | 6.4 | 2.8 | 1.29 |
| Atherosclerosis | 2.5 | 2.1 | 0.19 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.3 | 11.2 | 0.01 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.7 | 2.7 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.9 | 0.9 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.7 | 2.6 | 0.81 |
| Celiac Disease | 3.4 | 4 | -0.18 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 6.5 | 7.6 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3.1 | 0.68 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.8 | 2 | 0.4 |
| Chronic Urticaria (Hives) | 1.9 | 1.6 | 0.19 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1.3 | 0.38 |
| Cognitive Function | 2.5 | 1.6 | 0.56 |
| Colorectal Cancer | 8.3 | 2.7 | 2.07 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.9 | 3 | -0.03 |
| COVID-19 | 11.7 | 14.3 | -0.22 |
| Crohn's Disease | 9.7 | 6.4 | 0.52 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.1 | 1.9 | -0.73 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 2.6 | 1.4 | 0.86 |
| Denture Wearers Oral Shifts | 1.9 | 1.9 | |
| Depression | 13.6 | 11 | 0.24 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.4 | 2.5 | 0.36 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4 | 2.3 | 0.74 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.8 | 4.9 | 0.39 |
| gallstone disease (gsd) | 4.2 | 1.3 | 2.23 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.2 | 1.2 | 0.83 |
| Generalized anxiety disorder | 3.4 | 2.1 | 0.62 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.3 | 0.7 | 2.29 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2 | -1.22 |
| Halitosis | 1.6 | 0.3 | 4.33 |
| Hashimoto's thyroiditis | 4.1 | 1.9 | 1.16 |
| Heart Failure | 5.1 | 2.1 | 1.43 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.8 | 0.6 | 2 |
| hypercholesterolemia (High Cholesterol) | 1 | 0.4 | 1.5 |
| hyperglycemia | 2.9 | 1.7 | 0.71 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.2 | 6.5 | -0.25 |
| Hypothyroidism | 0.2 | 1 | -4 |
| Hypoxia | 3.7 | 0.3 | 11.33 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 10.3 | 11.3 | -0.1 |
| Insomnia | 2.5 | 3 | -0.2 |
| Intelligence | 1.9 | 0.6 | 2.17 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 9.2 | 5.9 | 0.56 |
| ischemic stroke | 3.1 | 1.7 | 0.82 |
| Liver Cirrhosis | 8.7 | 5.3 | 0.64 |
| Long COVID | 8.4 | 9 | -0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.4 | 0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.3 | 0.9 | 0.44 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.7 | 2 |
| Metabolic Syndrome | 8.9 | 9 | -0.01 |
| Mood Disorders | 13.4 | 9 | 0.49 |
| multiple chemical sensitivity [MCS] | 1.4 | 0.1 | 13 |
| Multiple Sclerosis | 8.4 | 7 | 0.2 |
| Multiple system atrophy (MSA) | 1.8 | 0.7 | 1.57 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.3 | -10 |
| Neuropathy (all types) | 0.9 | 2.2 | -1.44 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.4 | 5.4 | 0.19 |
| NonCeliac Gluten Sensitivity | 1.7 | 0.6 | 1.83 |
| Obesity | 12.2 | 9.9 | 0.23 |
| obsessive-compulsive disorder | 6.9 | 4.6 | 0.5 |
| Osteoarthritis | 3.3 | 1.4 | 1.36 |
| Osteoporosis | 2.5 | 1.7 | 0.47 |
| pancreatic cancer | 1 | 0.3 | 2.33 |
| Parkinson's Disease | 9.9 | 8.3 | 0.19 |
| Polycystic ovary syndrome | 7.9 | 3.4 | 1.32 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4 | 3.7 | 0.08 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.1 | 4.7 | 0.94 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.6 | 3.2 | 1.37 |
| scoliosis | 0.8 | 1.2 | -0.5 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.4 | 0.3 | 3.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.1 | 0.6 | 2.5 |
| Stress / posttraumatic stress disorder | 3.3 | 3.1 | 0.06 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1 | 0.3 | 2.33 |
| Type 1 Diabetes | 4.8 | 4.4 | 0.09 |
| Type 2 Diabetes | 10 | 8.3 | 0.2 |
| Ulcerative colitis | 6.7 | 8.3 | -0.24 |
| Unhealthy Ageing | 6.6 | 2.6 | 1.54 |
| Vitiligo | 2.5 | 1.7 | 0.47 |
